Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is an extremely challenging disease with a high mortality rate and a short overall survival time. The poor prognosis can be explained by aggressive tumor growth, late diagnosis, and therapy resistance. Consistent efforts have been made focusing on early tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Q., Maier, S. H., Li, P., Peterhansl, J., Belka, C., Mayerle, J., Mahajan, U. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409417/
https://www.ncbi.nlm.nih.gov/pubmed/32758252
http://dx.doi.org/10.1186/s13014-020-01624-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409417/
https://www.ncbi.nlm.nih.gov/pubmed/32758252
http://dx.doi.org/10.1186/s13014-020-01624-1

Ejemplares similares